UCI 趙 Chao Family Comprehensive Cancer Center

Heme Malignancy Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

Clinical Research Manager:
Blake Johnson

Clinical Research Coordinators:
Emiri Matsuda
Stephanie Osorio
Judit Castellanos
Kelsey McAbee
Regan Dagenhart
Harleen Mehrok
Alireza Saatchi

Data Coordinators:
Alice Ting
Heather Franson

Myeloproliferative Neoplasm

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Front Line

ETCTN 10538
Venetoclax+ASTX727 (All oral therapy) for CMML, PDS/MPN with excess blasts

Accrual: 0/5

Coord: Kelsey McAbee
Mechanism: BCL-2 selective inhibitor

Observational Study

UCI 23-32
Dissecting the mechanism of Interferon Alpha (IFN) response in MPN

Coord: N/A
Mechanism: observational study

Supportive Care

UCI 20-50
N-Acetylcysteine in MPN to Improve Disease Markers & Symptoms

Accrual 10/27

Coord: Kelsey McAbee
Mechanism: Mucolytic agent (cysteine and GSH precursor)

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

2nd Line+

UCI 20-51
IO-202 in R/R AML patients w/ monocytic differentiation and in R/R CMML patients

Accrual: 4/5

Coord: Stephanie Osorio
Mechanism: LILRB4 antibody

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Myelodysplastic Syndrome

High-Risk

UCI 22-151
LYT-200 in patients w/ R/R AML or high-risk MDS

Accrual: 3/5

Coord: Stephanie Osorio
Mechanism: Galectin-9 monoclonal antibody

HSCT

UCI 23-90
SAR445419 in high-risk myeloid malignancies undergoing HSCT

Accrual: 0/5

Coord: Emiri Matsuda
Mechanism: off-the-shelf NK cells

Low-Risk

UCI 21-239
IRAK 1/4 inhibitor, R289, in patients w/ refractory or resistant lower-risk MDS

Accrual:0/5

Coord: Stephanie Osorio
Mechanism: IRAk1/4 inhibitor

Molecularly-Driven

IDH

UCI 21-144
HMPL-306 in advanced hematological malignances w/ IDH mutations

Accrual: 0/5

Coord: Stephanie Osorio
Mechanism: IDH1/2 inhibitor

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Intensive

UCI 18-105
The combination of CPX-351 and Glasdegib in previously undertreated patients w/ AML w/ MDS related changes or therapy related AML

Accrual: 25/30

Coord: Kelsey McAbee
Mechanism: Hedgehog pathway inhibitor+liposomal formulation of cytoxic chemotherapy Danorubicin & Cytarabine

Non-Intensive

FLT3 mutation

UCI 21-216
Giltertinib+Venetoclax+Azacitidine in patients w/ FLT3 mutant AML not eligible for intensive induction chemotherapy

Accrual: 1/5

Coord: Stephanie Osorio
Mechanism: FLT3 inhibitor

CD123+

UCI 19-138
IMGN632 as monotherapy or combination w/ Venetoclax and/or Azacitidine for patients w/ CD123-positive AML

Accrual: 2/5

Coord: Stephanie Osorio
Mechanism: CD123 antibody

KMT2A-r/NPM1-m

UCI 23-44
Venetoclax/Azacitidine v.s Venetoclax+ KO-530 v.s cytarabine/daunorubicin (7+3)+ KO-539 in AML

Accrual: 0/6

Coord: Stephanie Osorio
Mechanism: menin inhibitor

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Acute Myeloid Leukemia

2nd Line+

UCI 22-151
LYT-200 in patients w/ R/R AML or high-risk MDS

Accrual: 3/5

Coord: Stephanie Osorio
Mechanism: Galectin-9 monoclonal antibody

UCI 22-81
HM43239 in patients w/ R/R AML

Accrual: 0/6

Coord: Stephanie Osorio
Mechanism: FLT3 inhibitor

UCI 23-154
Ziftomenib combinations for the KMT2A-rearranged/NPM1 mutant R/R AML

Accrual: 0/5

Coord: Stephanie Osorio
Mechanism: menin inhibitor

Molecularly-Driven

IDH

UCI 21-144
HMPL-306 in advanced hematological malignances w/ IDH mutations

Accrual: 0/5

Coord: Stephanie Osorio
Mechanism: IDH1/2 inhibitor

Menin

UCI 22-24
BMF-219 in patients w/ AL, DLBCL, MM, CLL/SLL

Accrual: 1/5

Coord: Judit Castellanos
Mechanism: menin inhibitor

Maintenance

UCI 22-183
Galinpepimut-S (GPS) maintenance monotherapy vs. investigator's choice of best available therapy

Accrual: 0/5 (opened 11/09/23)

Coord: Stephanie Osorio
Mechanism: WT-1 derived synthetic analog peptides

Molecularly-Driven

KMT2A-r/NPM1-m

UCI 23-44
Venetoclax/Azacitidine v.s Venetoclax+ KO-530 v.s cytarabine/daunorubicin (7+3)+ KO-539 in AML

Accrual: 0/6

Coord: Stephanie Osorio
Mechanism: menin inhibitor

High-Risk, HSCT

UCI 23-90
SAR445419 in high-risk myeloid malignancies undergoing HSCT

Accrual: 0/5

Coord: Emiri Matsuda
Mechanism: off-the-shelf NK cells

Salvage Therapy

UCI 19-93
DFP-10917 vs. non-intensive reinduction or intensive reinduction for AML patients in 2nd or 3rd salvage

Accrual: 11/12

Coord: Stephanie Osorio
Mechanism: Nucleoside analog

Acute Lymphoblastic Leukemia

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Ph+ only

EA9181
Steroids +TIKI w/ chemotherapy or Blinatumomab for BCR-ABL positive adult patients

Accrual 11/35

Coord: Judit Castellanos
Mechanism: BiTE binding to CD19 (on B-cell) and CD3 (on T-cells) and PD-1 inhibitor

Ph- only

UCI 21-98
Blinatumomab altering w/ low-intensity chemotherapy vs. SOC for older adult patients

Accrual: 5/6

Coord: Judit Castellanos
Mechanism: BiTE binding to CD19 (on B-cell) and CD3 (on T-cells) and PD-1 inhibitor

UCI 22-125
Calaspargase pegol for tx of adults 22-65y/o w/ newly diagnosed Ph- ALL

Accrual: 0/5

Coord: Judit Castellanos
Mechanism: PEGylated conjugate L-asparaginase

Ph+ or Ph-

A041501
Addition of Inotuzumab Ozogamicin to frontline therapy in young adults (18-39y/o)

Accrual: 10/15

Coord: Judit Castellanos
Mechanism: conjugated anti-CD22 monoclonal antibody

UCI 21-14
Levocarnitine for Asparaginase hepatoxicity in ALL patients

Accrual: 0/5 (opened 11/3/23)

Coord: Judit Castellanos
Mechanism: Oxidative stress reducer & inflammatory modulator

Acute Lymphoblastic Leukemia

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

CR w/ MRD+

UCI 20-34
Outpatient Blinatumomab in adult patients w/ MRD of pre B-ALL in CR

Accrual: 2/5

Coord: Judit Castellanos
Mechanism: BiTE binding to CD19 (on B-cell) and CD3 (on T-cells) and PD-1 inhibitor

Molecularly-Driven

CD22+

A041703
Inotuzumab Ozogamicin followed by Blinatumomab for ph- CD22-positive newly diagnosed or R/R ALL patients

Accrual: 1/5

Coord: Judit Castellanos
Mechanism: antibody-druf conjugate combining a monoclonal antibody tartgeting CD22 on B-lymphoblast with the cytoxic agents

Menin

UCI 22-24
BMF-219 in patients w/ AL, DLBCL, MM, CLL/SLL

Accrual: 1/5

Coord: Judit Castellanos
Mechanism: menin inhibitor

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

High-Risk

S1925
Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Accrual: 1/10

Coord: Stephanie Osorio
Mechanism: BCL2 inhibitor +anti-CD20 monoclonal antibody

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Chronic Lymphocytic Leukemia

Molecularly-Driven

Menin

UCI 22-24
BMF-219 in patients w/ AL, DLBCL, MM, CLL/SLL

Accrual: 1/5

Coord: Judit Castellanos
Mechanism: menin inhibitor

Cell Therapy

UCI 21-19
MB-106 in patients w/ R/R CD20+ B-cell NHL or CLL

Accrual: 1/5

Coord: Regan Dagenhart
Mechanism: anti-CD20 chimeric antigen receptor

2nd Line+

UCI 21-209
LOXO-305 + Venetoclax and Rituximab vs. Venetoclax and Rituximab in previously treated CLL/SLL

Accrual: 1/3

Coord: Stephanie Osorio
Mechanism: BTK inhibitor + BCL2 inhibitor + CD20 marker

3rd Line+

UCI 22-134
Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 1/5

Coord: Emiri Matsuda
Mechanism: BTK inhibitor for both wild-typ and C481S-mutant type

UCI 20-198
NX-2127, Bruton's tyrosine kinase degrader, in adults w/ R/R B-cell malignancies

Accrual: 1/3

Coord: Stephanie Osorio
Mechanism: BTK degrader + iMiD

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

2nd Line+

UCI 23-167
Phase I- TERN-701 in patients w/CML

Accural: N/A

Coord: Stephanie Osorio
Mechanism: STAMP inhibitor

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Maintenance

S1803
Daratumumab/rHuPH20 + lenalidomide vs. lenalidomide as post auto ASCT maintenance therapy

Accrual: 10/15

Coord: Judit Castellanos
Mechanism: anti-CD38 monoclonal antibody

Molecularly-Driven

Menin

UCI 22-24
BMF-219 in patients w/ AL, DLBCL, MM, CLL/SLL

Accrual: 1/5

Coord: Judit Castellanos
Mechanism: menin inhibitor

2nd Line+

UCI 22-190
Teclistamab monotherapy vs. PVD or KD in patients received 1-3 prior lines of therapy

Accrual: 2/3

Coord: Emiri Matsuda
Mechanism: CD3 x BCMA BiTE

Multiple Myeloma

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

Front Line

UCI 23-17
Odronextamab (REGN1979) vs. investigator's choice in patient w/ FL

Coord: Emiri Matsuda
Mechanism: Anti-CD20 x Anti-CD3 bispecific antibody

Follicular Lymphoma

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Follicular Lymphoma

Cell Therapy

UCI 21-19
MB-106 in patients w/ R/R CD20+ B-cell NHL or CLL

Accrual: 1/5

Coord: Regan Dagenhart
Mechanism: anti-CD20 **chimeric antigen receptor**

UCI 22-01
Axicabtagene Ciloleucel vs. SOC in patients w/ R/R FL

Accrual: 0/5

Coord: Regan Dagenhart
Mechanism: anti-CD19 **CAR T-cell**

3rd Line+

UCI 22-134
Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 1/5 (opened 11/21/23)

Coord: Emiri Matsuda
Mechanism: BTK inhibitor for both wild-typ and C481S-mutant type

UCI 20-198
NX-2127, Bruton's tyrosine kinase degrader, in adults w/ R/R B-cell malignancies

Accrual: 1/3

Coord: Regan Dagenhart
Mechanism: BTK degrader + iMiD

Consolidation

S2114
Consolidation therapy following CD19 CAR T-cell tx

Accrual: 0/6

Coord: Emiri Matsuda
Mechanism: bite/mab

Molecularly-Driven

UCI 21-04
Nanatinostat + Valganciclovir in patients w/ EBV+ R/R lymphomas

Accrual: 0/2

Coord: Regan Dagenhart
Mechanism: selective HDAC class I inhibitor

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Marginal Zone Lymphoma

Cell Therapy

UCI 21-19
MB-106 in patients w/ R/R CD20+ B-cell NHL or CLL

Accrual: 1/5

Coord: Regan Dagenhart
Mechanism: anti-CD20 **chimeric antigen receptor**

3rd Line+

UCI 22-134
Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 1/5

Coord: Emiri Matsuda
Mechanism: BTK inhibitor for both wild-typ and C481S-mutant type

UCI 20-198
NX-2127, Bruton's tyrosine kinase degrader, in adults w/ R/R B-cell malignancies

Accrual: 1/3

Coord: Regan Dagenhart
Mechanism: BTK degrader + iMiD

Molecularly-Driven

UCI 21-04
Nanatinostat + Valganciclovir in patients w/ EBV+ R/R lymphomas

Accrual: 0/2

Coord: Regan Dagenhart
Mechanism: selective HDAC class I inhibitor

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Cell Therapy

UCI 21-19
MB-106 in patients w/ R/R CD20+ B-cell NHL or CLL

Accrual: 1/5

Coord: Regan Dagenhart
Mechanism: anti-CD20 chimeric antigen receptor

3rd Line+

UCI 22-134
Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 1/5

Coord: Emiri Matsuda
Mechanism: BTK inhibitor for both wild-typ and C481S-mutant type

Molecularly-Driven

UCI 21-04
Nanatinostat + Valganciclovir in patients w/ EBV+ R/R lymphomas

Accrual: 0/2

Coord: Regan Dagenhart
Mechanism: selective HDAC class I inhibitor

Mantle Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

75 y/o Older

S1918
R-miniCHOP w/ or w/o oral Azacititine in patients 75 y/o or older

Accrual: 3/10

Coord: Regan Dagenhart
Mechanism: Oral hypomethylating agent

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Primary Relapsed/Refractory

UCI 21-225
Glofitamab+ R-ICE in patients w/ R/R transplant eligible DLBCL

Accrual: 7/10

Coord: Regan Dagenhart
Mechanism: T-cell bispecific antibody targeting CD20 (B-cell) and CD3ε chain T-cell)

Secondary Relapsed/Refractory

UCI 21-19
MB-106 in patients w/ R/R CD20+ B-cell NHL or CLL

Accrual: 1/5

Coord: Regan Dagenhart
Mechanism: anti-CD20
CHIMERIC ANTIGEN RECEPTOR

UCI 20-126
CB-010, CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy

Accrual: 5/7

Coord: Emiri Matsuda
Mechanism: anti-CD19
CHIMERIC ANTIGEN RECEPTOR

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Tertiary Relapsed/Refractory

UCI 22-24
BMF-219 in patients w/ AL, DLBCL, MM, CLL/SLL

Accrual: 1/5

Coord: Stephanie Osorio
Mechanism: menin inhibitor

S2114
Consolidation therapy following CD19 CAR T-cell tx

Accrual: 0/6

Coord: Emiri Matsuda
Mechanism: bite/mab

UCI 20-198
NX-2127, Bruton's tyrosine kinase degrader, in adults w/ R/R B-cell malignancies

Accrual: 1/3

Coord: Regan Dagenhart
Mechanism: BTK degrader + iMiD

Molecularly-Driven

UCI 21-04
Nanatinostat + Valganciclovir in patients w/ EBV+ R/R lymphomas

Accrual: 0/2

Coord: Regan Dagenhart
Mechanism: selective HDAC class I inhibitor

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

UCI 21-04
Nanatinostat + Valganciclovir in patients w/ EBV+ R/R lymphomas

Accrual: 0/2

Coord: Regan Dagenhart
Mechanism: selective HDAC class I inhibitor

Basket study

Primary Mediastinal B-Cell Lymphoma

Newly diagnosed

Open to Accrual | Low Accruing | Pending Activation/Suspended

COG ANHL1931
Nivolumab + chemo-immunotherapy

Accrual: 1/5

Coord: Regan Dagenhart
Mechanism: PD1 inhibitor

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Consolidation

S2114
Consolidation therapy following CD19 CAR T-cell tx

Accrual: 0/6

Coord: Emiri Matsuda
Mechanism: bite/mab

Molecularly-Driven

UCI 21-04
Nanatinostat + Valganciclovir in patients w/ EBV+ R/R lymphomas

Accrual: 0/2

Coord: Regan Dagenhart
Mechanism: selective HDAC class I inhibitor

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Cell Therapy

UCI 21-19
MB-106 in patients w/ R/R CD20+ B-cell NHL or CLL

Accrual: 1/5

Coord: Regan Dagenhart
Mechanism: anti-CD20 chimeric antigen receptor

3rd line+

UCI 22-134
Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 1/5 (opened 11/21/23)

Coord: Emiri Matsuda
Mechanism: BTK inhibitor for both wild-typ and C481S-mutant type

UCI 20-198
NX-2127, Bruton's tyrosine kinase degrader, in adults w/ R/R B-cell malignancies

Accrual: 1/3

Coord: Regan Dagenhart
Mechanism: BTK degrader + iMiD

Molecularly-Driven

UCI 21-04
Nanatinostat + Valganciclovir in patients w/ EBV+ R/R lymphomas

Accrual: 0/2

Coord: Regan Dagenhart
Mechanism: selective HDAC class I inhibitor

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

Molecularly-Driven

UCI 21-04
Nanatinostat + Valganciclovir in patients w/ EBV+ R/R lymphomas

Accrual: 0/2

Coord: Regan Dagenhart
Mechanism: selective HDAC class I inhibitor

Relapsed/Refractory

Open to Accrual | Low Accruing | Pending Activation/Suspended

2nd Line+

UCI 21-224
KT-333 in R/R lymphomas, LGLL and solid tumors

Accrual: 0/5

Coord: Regan Dagenhart
Mechanism: STAT3 degrader

3rd Line+

UCI 21-99
ONO-4685 given as monotherapy

Accrual: 1/10

Coord: Regan Dagenhart
Mechanism: CD3-bispecific antibody targeting PD-1

Molecularly-Driven

UCI 21-04
Nanatinostat + Valganciclovir in patients w/ EBV+ R/R lymphomas

Accrual: 0/2

Coord: Regan Dagenhart
Mechanism: selective HDAC class I inhibitor

UCI 21-144
HMPL-306 in advanced hematological malignances w/ IDH mutations

Accrual: 0/5

Coord: Stephanie Osorio
Mechanism: IDH1/2 inhibitor

Supportive Care

Supportive Care

UCI 14-03
Role of Inflammation in the Pathogenesis of Myeloproliferative Neoplasm

UCI 15-65

Effect of candidate blood cancer therapies on normal human lymphocytes

Long-Term FU

UCI 21-184
Long-term safety of CAR-T inpatient w/ heme malignancies

Accrual: 2/5

Coord: Emiri Matsuda

UCI 21-90
Risk-ADAPTed conditionin regimen for AHSCT

Accrual: 4/48

Coord: Emiri Matsuda

Open to Accrual | Low Accruing | Pending Activation/Suspended

Polycythemia vera

UCI 21-204
ISIS702843 in patients w/ PD-PC

Mechanism: Antisense oligonucleotide specific for human transmembrane protease serine 6

Accrual: 1/5
Coord: Kelsey McAbee

Basket study

HSCT Transplant

UCI 22-188
Prospective evaluation of CMV-TCIP directed Letemovir ppx after AHCT

Coord: Emiri Matsuda
Mechanism: anti-CMV

Other